Zanidatamab, a bispecific anti-HER2 antibody that simultaneously binds two non-overlapping HER2 epitopes, is used to treat HER2-positive G/GEJ adenocarcinoma. This evidence concerns the gene ERBB2 and adenocarcinoma.